Zacks Investment Research
06 Aug 2026, 16:51 UTC · 1h ago
ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Aug 2026, 16:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AbbVie lowered its full-year 2026 EPS guidance to a range of $13.87-$14.07 from $13.91-$14.11. — Lowering earnings guidance typically triggers immediate negative price action as investors re-evaluate valuation models.
-0.40AbbVie raised its full-year revenue guidance by $300 million to $67.6 billion. — Increased revenue projections indicate strong top-line momentum and market demand for products.
+0.30AbbVie expects combined 2026 sales for Skyrizi and Rinvoq to exceed $31 billion, representing over 20% growth. — Strong growth in these key immunology drugs proves the company is successfully diversifying away from Humira's exclusivity loss.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
AbbVie is expected to close the acquisition of Apogee Therapeutics (APGE) within the current quarter. — Acquisitions typically signal strategic growth and pipeline expansion, though the immediate cost impacted EPS guidance.
Which stocks this story touches
The company is the target of an acquisition by AbbVie.
Despite strong Q2 results and revenue guidance, the stock declined due to lowered full-year EPS guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
